BioSpace News Archive

Precision Molecular, Inc. (PMI), a clinical-stage company with the mission to develop imaging biomarkers and theranostics, today announced that the Alzheimer’s Drug Discovery Foundation (ADDF) made an investment in the company to support advancement of more effective ways to image neuroinflammation, with a view to discovery of early imaging biomarkers for Alzheimer’s disease

Sojournix, a clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative new medicines for the treatment of women’s health and neuroendocrine disorders, announces that Daniel Grau, Chief Executive Officer of Sojournix, will present at the Cowen and Company 40th Annual Health Care Conference on Wednesday, March 4

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that full results from its Phase 2 clinical trial of zilucoplan in patients with generalized myasthenia gravis (gMG) were published online in JAMA Neurology.

ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced that the U.S. Food and Drug Administration (FDA) has granted two Fast Track designations for its lead candidate, ALX148, for the first-line treatment of patients with head and neck squamous cell carcinoma (HNSCC), and for the second-line treatment of patients with HER2-positive gastric or gastroesophageal junction (gastric/GEJ) carcinoma

Pear Therapeutics, Inc., the leader in prescription digital therapeutics (PDTs), today announced that Corey McCann, M.D., Ph.D., President and CEO will give a corporate presentation and participate in a digital therapeutics panel discussion at the Cowen and Company 40th Annual Healthcare Conference.

Baxter International Inc. (NYSE:BAX), a leading global medical products company, has completed its previously announced acquisition of Seprafilm Adhesion Barrier and related assets from Sanofi for $350 million

As the novel coronavirus outbreak in Wuhan spreads, Sunon Charity Foundation acted quickly and in unity to fight against this disease. On January 28, Sunon provided an initial $1.43million to relief and containment efforts.

Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), is pleased to announce that it has completed (the “Completed Agreement”) the previously announced acquisition (the “Acquisition”) of all of the assets of Neuro-Pro Monitoring (Neuro-Pro), one of the largest IONM service providers in Texas.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced the final data from its CTCL clinical trial of WP1220 for the treatment of cutaneous T-cell lymphoma (CTCL)

Abbott (NYSE: ABT) today announced it has received CE Mark for the new Gallant™ implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices, bringing the most advanced heart rhythm management capabilities along with a new set of benefits to people in Europe with abnormal heart rhythms and heart failure.